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ABSTRACT 
Traditionally, the internal research and development (R&D) departments of multinational 
companies (MNCs) have served as a main driver of MNCs innovative capacity. Today’s high 
pace of change and competitive landscape have forced MNCs however to look beyond their 
organizational boundaries and to involve external organizations in their R&D for technological 
advancement and innovation. In particular, MNCs are using R&D collaborations as a means to 
create and access new knowledge. Collaborations are particularly relevant in science-based 
sectors such as the pharmaceutical industry where R&D mainly relies on complex and basic 
scientific knowledge. In this sector, the sources of expertise are widely dispersed and drug 
discovery and development requires coordination between different actors. The globalization 
trend has facilitated collaborations across long distances and companies have adopted a 
combination of long and short distance collaborations in their innovation process. 
The role of geographic proximity in collaboration continues to puzzle researchers. In fact, it 
may be more complex than previously addressed in the literature, most of which has considered 
external collaborations in a MNC as a homogenous entity in terms of knowledge. A MNC 
consists of different R&D units that specialize in different research areas and are active at 
different stages of the innovation process. Furthermore, a MNC collaborates with a large 
variety of external organizations and individuals. Thus, R&D collaborations in a MNC can be 
considered heterogeneous in terms of the knowledge and actors involved. The various types of 
knowledge and actors well differ in how important the role of geographic proximity is for 
successful collaborations. 
This thesis studies the role of geographic proximity in the R&D collaborations of MNCs when 
creating, accessing and embedding different types of knowledge. In particular, I examine these 
aspects by differentiating between (1) the nature of knowledge (basic science vs clinical 
science, core vs explorative knowledge), and (2) the actors involved on the organization level 
(university, hospital, research institute and company) as well as on the individual level (star 
scientists). The different levels of analysis describe different aspects of the R&D collaboration 
and how these affect the internal knowledge of MNCs. 
I used co-publications and patents as a proxy for R&D collaborations and analysed the role of 
geographic proximity using descriptive, social network and econometric analysis. The results 
show an increasing openness of pharmaceutical MNCs to collaborate over the past 20 years in 
terms of the organizations and countries involved in drug discovery and development. While 
the main patents behind innovative drugs are still mainly owned by companies themselves, 
external organizations increasingly contribute indirectly to knowledge creation, as visible from 
an increasing proportion of cited patents and publications from external organizations. This 
substitutes for biotech and pharmaceutical companies decreasing investments in R&D. 
Furthermore, considering the nature of knowledge, the results show that collaborations in basic 
science and core knowledge areas are more positively affected by geographic proximity than 
collaborations within clinical science and knowledge exploration of the MNCs. I also find that 
different types of actors embed different natures of knowledge. The knowledge accessed by 
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MNCs from universities is more positively affected by geographic proximity during the 
collaborative process, compared to hospitals or companies. However, highly skilled individual 
scientists who work at MNCs (star scientists), can help to maintain local collaborations. 
Based on these findings I conclude that the role of geographic proximity in R&D collaborations 
of MNCs varies between the types of collaboration and must be more precisely assessed 
distinguishing between each R&D collaboration between a MNC and another organization or 
actor. This thesis underlines the crucial role of R&D collaborations for MNCs and emphasizes 
the importance of geography for the R&D management of MNCs to create and access 
knowledge effectively in collaborations. From a policy perspective, the importance of different 
knowledge types in R&D collaborations should be kept in mind when facilitating the 
development of R&D collaborations, particularly when local actors are trying to attract foreign 
MNCs.  
 
Keywords: R&D collaborations; geographic proximity; knowledge; multinational companies; 
pharmaceutical industry. 
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LIST OF ABBREVIATIONS 
DID Difference-in-difference model. 
FDA Food and Drug Administration (US regulatory agency). 
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NDA New drug application. 
NME New molecular entity.  
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SNA Social network analysis. 
US United States. 
USPTO United States Patent and Trademark Office. 

  
 
 
LIST OF DEFINITIONS 
R&D collaboration  Active participation by two or more partners in a joint 
R&D or innovation project (Cassiman and Veugelers, 
2002). 
External organization An organization that collaborates in R&D with a MNC. 
This organization can be a university, hospital, research 
institute, industry, agency or foundation.  
Knowledge source An organization that contributes to the knowledge behind a 
NME. It can be the assignee of a main or cited patent or the 
affiliation of an author in a cited scientific publication. 
Direct knowledge source An organization involved directly in the drug development 
process of a NME, as the assignee of the main patent behind 
a NME. 
Indirect knowledge source An organization involved indirectly as the assignee of a 
cited patent or the affiliation of an author in a cited 
scientific publication of the main patent behind a NME. 
Organization granted NME An organization that sponsors the development or grants 
the FDA approval of a NME. 
Internal knowledge source An organization that grants the NME or an organization 
that merges or is acquired by an organization that grants the 
NME. 
External knowledge source An organization other than the one that grants the NME. 
Shared knowledge source An organization that appears as a knowledge source for 
multiple NMEs in the same year. 
Age of the knowledge source Age is calculated as the difference between the approval 
year of the NME and the year of the priority date or 
publication year of the main patents or prior art (for patents 
this is the priority year and for scientific publications the 
publication year). 
Basic science knowledge  Knowledge type refers to the understanding of a 
phenomenon. This often takes place during the first phases 
of the drug discovery process. 
Clinical science knowledge area Knowledge type also called applied knowledge refers to the 
knowledge for a specific end-use. In the drug discovery and 
development process is related to clinical trials, where 
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compounds are tested on humans to assess the safety and 
efficacy of a drug.  
Core knowledge areas Defined by March (1991) as exploitative knowledge: the 
use and development of things already known. This 
knowledge is the main source of innovation for companies. 
Exploration knowledge areas  Defined by March as ‘a pursuit of new knowledge for the 
company’ (1991). It represents the knowledge in a new 
therapeutic area in which the company decides to diversify 
its market offer. 
Local collaborator An external organization located less than 100 km from a 
closed or control R&D site. 
 
1 
1 INTRODUCTION 
Knowledge has long been regarded as the most critical asset for an organization and one of the 
principal sources behind companies’ competitive advantage (Teece, 1992; Grant, 1996b). 
Firms innovate by combining existing and new knowledge (Schumpeter, 1942; Nelson and 
Winter, 1982; Henderson and Clark, 1990). In large multinational companies (MNCs) that 
operate in science-based industries, such as pharmaceutical and biotechnology firms, the 
combination and creation of knowledge mostly occur as part of research and development 
(R&D) activities (Cohen and Levinthal, 1989; Rosenberg, 1990). However, with the increasing 
complexity of products and technologies, in-house R&D is not enough to create innovation 
because knowledge is distributed across different fields and organizations (Nooteboom, 2009). 
Companies therefore increasingly access and use external knowledge to complement their in-
house expertise and increase their competitive advantage (Freeman, 1991; Powell and Grodal, 
2005). 
R&D collaborations – the main focus of this thesis – are considered to be one of the most 
important conduits for accessing and using external knowledge. R&D collaborations are 
defined as “active participation by both partners in a joint R&D or innovation project” 
(Cassiman and Veugelers, 2002). These partnerships allow for mutually beneficial exchanges 
in arrangements where both sides make long-term investments (Hagedoorn and Duysters, 
2002; Nooteboom, 2004). They are not only about the creation of new knowledge but also 
about firms accessing existing knowledge from a variety of individuals and external 
organizations such as universities, research institutes, other firms and competitors (Duysters 
and Lokshin, 2011). 
Previous studies have shown that R&D collaborations have become an increasingly critical 
element in the innovation strategies of firms (Powell, Koput and Smith-Doerr, 1996; 
Chesbrough, 2003). The knowledge from R&D collaborations contributes to different 
performance outcomes including innovation, technological advances (Powell, Koput and 
Smith-Doerr, 1996; Duysters and Lokshin, 2011), patenting (Gittelman and Kogut, 2003) and 
organizational growth or failure (Mitsuhashi and Greve, 2009). R&D collaborations are also a 
constitutive part of open innovation models that companies use to access external knowledge 
such as recruitment, acquisition and formal as well as informal exchanges with other 
organizations (Chesbrough, 2003). Considering the crucial importance of R&D collaboration 
for innovation strategies, a key question for firms is how to create and assimilate knowledge 
effectively from R&D collaborations (Arora and Gambardella, 1990; Powell, Koput and 
Smith-Doerr, 1996). 
In an attempt to answer this question, many scholars have debated the role of geographic 
proximity in a firm’s ability to access external knowledge (Boschma, 2005; Ponds, van Oort 
and Frenken, 2007; Balland, Boschma and Frenken, 2015). One stream of literature has argued 
that geographic proximity and clustering facilitates collaborations because face-to-face and 
social interactions create the trust that is important for collaborations (Porter, 1998; Zucker, 
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Darby and Armstrong, 1998; Rosenfeld, 2005). In contrast, several authors have argued that 
geographic proximity is neither a necessary nor sufficient condition for collaboration and 
innovative performance. Local collaborations may become more valuable if the company uses 
also distant interactions that facilitate the variety of ideas and decrease the problem of spatial 
knowledge lock-in (Bathelt, Malmberg and Maskell, 2004; Owen-Smith and Powell, 2004; 
Boschma, 2005). Moreover, advances in information and telecommunication technologies and 
the integration of global markets have contributed to the adoption of a combination of local 
and distant collaborations by MNCs. Thus, the spatial aspect of knowledge involved in R&D 
collaborations appears to be more complex than what previously has been indicated.  
The starting point of this thesis is therefore that the proper role of the geographic dimension in 
R&D collaborations must be more precisely assessed in relation to different types of 
knowledge. This is particularly relevant within the context of MNCs (Buckley and Carter, 
2004). MNCs are characterized by different R&D units that specialize in different research 
areas and that are active at different stages of the innovation process. Thus, the knowledge 
MNCs maintain is heterogeneous. Furthermore, the R&D collaborations of MNCs tend to 
involve a variety of external organizations and individuals from which the company aims to 
access specific types of knowledge. So far the literature looking at geographic proximity has 
not considered this heterogeneity of knowledge acquired by MNCs through their R&D 
collaborations. 
One way of filling this gap in the context of MNCs is to focus on the diversity of each R&D 
collaboration and consider the differences in the type of knowledge created, accessed and 
embedded within these partnerships. Thus, the different research areas that the MNCs are active 
in are characterized by different natures of knowledge. Also, the variety of actors from which 
the MNCs access knowledge need to be taken into consideration, since they may embed 
different natures of knowledge as well as different institutional norms and values with regard 
to R&D collaboration and knowledge creation. In this context, the pharmaceutical sector – the 
research setting for this thesis – provides a particular case in which to study collaborations as 
pharmaceutical MNCs are considered one of the most research-based sectors, carrying out a 
high proportion of collaborative R&D activities (Kessel, 2011).  
In the geography literature, different types of knowledge have only been indirectly taken into 
account when studying R&D collaborations. Some have argued that geographic proximity is 
important in knowledge transfer because of the difficulty of transferring tacit knowledge 
(Polanyi, 1966). However, a more comprehensive study at the R&D collaboration level, 
looking at the types of knowledge in each collaboration, is required. 
To fill these gaps, this thesis investigates the role of geographic proximity in the R&D 
collaborations of pharmaceutical MNCs when they create, access and embed different types of 
knowledge. In particular, it studies the role of geographic proximity in relation to R&D 
collaborations, looking at (1) the nature of knowledge referring to the type of knowledge 
created from R&D collaboration; (2) the actors involved at the organization level, called 
external organizations, referring to the type of knowledge that MNCs access from external 
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organizations in R&D collaboration; and on individual level referring to the type of knowledge 
that is embedded within individuals in the MNCs in the R&D collaborations. These different 
levels of analysis describe different aspects of R&D collaborations. My main argument is that 
the role of geographic proximity varies depending on the type of knowledge created, accessed 
and embedded by MNCs in R&D collaborations. 
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2 BACKGROUND 
2.1 R&D COLLABORATIONS 
For firms in science-based industries, R&D collaboration is a crucial path to innovation. 
Accordingly, the number of R&D partnerships has risen steadily in firms, while internal R&D 
has declined (Chesbrough, 2003; Tijssen, 2009; Simpson and Reichman, 2013; Rafols et al., 
2014; Crescenzi, Nathan and Rodríguez-Pose, 2016). For example, Crescenzi, Nathan, and 
Rodríguez-Pose (2016) studied patents in the UK and observed that the ‘co-invented patents’ 
across all major technology fields made up around 25% of all patents in 1978 and over 67% in 
2007. Rafols et al., (2014) reviewed the publication activities of the R&D laboratories of major 
European and US pharmaceutical firms during the period 1995–2009. They observed a 
growing trend of collaborations and the overall reduction of in-house knowledge production. 
Furthermore, this study has shown that in addition to an increase in collaborations, 
pharmaceutical companies allow their partners to serve as the first authors of publications, 
taking the lead in an increasing proportion of projects (Rafols et al., 2014).  
The importance of collaborations has generated a lot of attention in the literature, with several 
motives for the establishment of collaborations in companies listed. The most widely cited 
reason for a company to work with others is the creation of and access to knowledge from 
external organizations (Hamel, 1991; Hagedoorn, 1993; Mowery, Oxley and Silverman, 1996). 
Firms are also heavily engaged in R&D collaborations to share risks, obtain access to new 
markets and technologies, speed up the process of product development and pool 
complementary skills (Cantwell, 1995; Pittaway et al., 2004; Dahlander and Gann, 2010; 
Cantner and Rake, 2014). Furthermore, the literature shows that the innovation advantage of 
R&D collaborations is a signal to the market, as well as to potential partners, of both the firm’s 
activities and products (Pittaway et al., 2004). 
In combination with increased collaborations, globalization has facilitated collaborations at 
greater geographic distances. Firms and in particular MNCs are increasingly combining local 
and long-distance collaborations in their R&D activities (Gertler, 2003; Bathelt, Malmberg and 
Maskell, 2004; Owen-Smith and Powell, 2004; Boschma, 2005). Moreover, companies have 
also invested in their ability to integrate knowledge dispersed across different locations to 
translate the advantage of the geographic dispersion of R&D activities into innovation (Singh, 
2008). These trends have drawn attention to the geographic proximity of R&D collaborations 
in the literature and have developed into a debate on its role. 
2.2 GEOGRAPHIC PROXIMITY IN R&D COLLABORATIONS 
Authors have typically argued that innovation is a highly localized phenomenon and 
geographic proximity factors into the success of collaborations (Jaffe et al., 1993; Audretsch 
and Feldman, 1996; Ponds, van Oort and Frenken, 2007). In particular, the importance of 
geographic proximity in R&D collaborations is most often explained by the fact that short 
geographic distances facilitate face-to-face and social interactions that form a basis to build 
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trust between companies and external organizations (Porter, 1998; Boschma, 2005; Rosenfeld, 
2005; Ponds, van Oort and Frenken, 2007)  
Further, geographic proximity has been considered important for knowledge access and 
creation. First, it facilitates access to highly skilled people, who can be recruited from local 
environments (Tijssen, 2009). Second, short distances are crucial for knowledge creation 
between organizations in clusters. Clusters are defined by Porter (1998) as ‘a geographically 
proximate group of interconnected companies and associated institutions in a particular field’. 
Following the seminal insight by Marshall (1927), the literature on clustering argues that ‘there 
is something in the air’ meaning that the knowledge creation is promoted when firms and 
individual are located in clusters (Maskell and Malmberg, 1999; Gertler, 2003; Martin and 
Moodysson, 2011). Authors suggest that clusters allow geographic proximity between 
organizations, beneficial for the creation and the rapid diffusion of new knowledge  (Krugman, 
1998). Hence, in these clusters, tacit knowledge can be easily diffuse through social and 
spontaneous meetings without collaborations, because it is ‘in the air’. The importance of this 
is evidenced by the observation that companies located in knowledge clusters have a higher 
innovation performance (Jaffe et al., 1993; Acs, Audretsch and Feldman, 1994). 
In contrast to these streams of literature, Boschma (2005) does not consider geographic 
proximity a necessary or sufficient condition for facilitating innovative activities. In particular, 
he proposes a proximity framework exploring the role of geographic proximity in combination 
with non-spatial dimensions such as cognitive, organizational, social and institutional 
proximity. The presence of such proximities between two organizations can compensate for 
the lack of geographic proximity between them (Boschma, 2005). 
Another body of literature declares the ‘end to the tyranny of distance’ (Cohen and Cairncross, 
1997; Stark and Castells, 1997) due to increasing advances in information and communication 
technologies. As a result of such advances, firms and in particular MNCs increasingly combine 
local and long-distance R&D collaborations(Gertler, 2003; Bathelt, Malmberg and Maskell, 
2004; Owen-Smith and Powell, 2004; Boschma, 2005). 
Local collaborations may be more valuable for a company if they are coupled with 
geographically distant partnerships that facilitate the merger of ideas and reduce the problem 
of spatial knowledge lock-in (Boschma, 2005). One example is the case of the Boston 
biotechnology industry where companies combine local and regional interactions with strategic 
partnerships with interregional and international actors (Owen-Smith and Powell, 2004). 
Several authors demonstrate that papers’ citations, often used as an indicator of scientific 
quality, rise due to international collaboration (Narin, Stevens and Whitlow, 1991; Katz and 
Hicks, 1997; Iorio et al., 2012). Malmberg and Maskell (2002) argue that long-distance 
interactions facilitate a mixture in the knowledge base of companies. Furthermore, distant 
collaborations allow the firms to learn about market trends and the newest technologies 
(Bathelt, Malmberg and Maskell, 2004). Therefore, relationships over longer geographic 
distances may entail higher costs, but this can be repaid by innovation, which might happen 
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accessing to both new knowledge and collaboration with highly competent researchers in long-
distance interactions. 
2.3 TYPES OF KNOWLEDGE AND GEOGRAPHIC PROXIMITY 
Despite being a well-researched topic, the role of geographic distance in R&D collaborations 
continues to puzzle researchers. Because firms and, in particular, MNCs, have adopted a 
combination of local and distant collaborations, it appears that the role of geographic proximity 
is more complex and cannot be generalized for all collaborations in a firm. One limitation of 
previous studies on geographic proximity is that they do not study the collaboration behind the 
firm-level and thus they treat external collaborations as a black box. More specifically, the 
majority of studies assume that internal collaborations and the actors involved are similar, 
ignoring the fact that external collaborations are context-dependent and can be characterized 
internally by types of knowledge (Mattes, 2012). As a consequence, it remains unclear what 
type of R&D collaborations are organized on a more local level and which collaborations tend 
to be more globally organized. Thus, to move beyond a firm-level analysis, a more 
comprehensive study is required. 
The study of the role of geographic proximity in each collaboration depending on the type of 
knowledge involved is particularly relevant for MNCs. These companies combine different 
types of knowledge from various disciplines within the same institution and their collaborations 
involve a variety of external organizations and individuals. R&D collaborations can be studied 
taking the following different aspects into account: (1) the nature of knowledge (e.g. the type 
of knowledge created from R&D collaboration); (2) the actors involved (a) at the organizational 
level, called external organizations (e.g. the type of knowledge that MNCs access from external 
organizations through R&D collaboration); (b) individual actors (e.g. the type of knowledge 
that is embedded within individuals in the MNCs R&D collaborations). These three aspects 
address the role of geographic proximity in R&D collaborations in more depth. 
In the next section, the different types of knowledge in R&D collaborations and their 
geographic aspect are explained in detail. 
2.3.1 Nature of knowledge  
The nature of knowledge refers to the characteristics of the knowledge created from R&D 
collaboration in a firm. For example, in the pharmaceutical sector, MNCs divide their R&D 
structure into therapeutic areas that produce different types of knowledge that are often located 
at separate R&D sites.  
The most common distinction of the nature of knowledge can be found in the work of 
philosopher Michael Polanyi (1966) that differentiates between two categories: tacit and 
codified knowledge. The first is associated with experience, embedded in practice, skills, 
emotions and human interactions, and cannot be adequately articulated by verbal means 
(Polanyi, 1966). It can hardly be formalized and transmitted because it is closely embedded in 
individuals. Codified knowledge, by contrast, is the ‘knowledge about’, easily understood 
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because it can be transferred by written documents (David and Foray, 1995). Looking at the 
knowledge in R&D collaborations, tacit knowledge is mostly spread through face-to-face 
meetings and personal relations that need partners at geographic proximity (von Hippel, 1994; 
Feldman and Lichtenberg, 2000). Codified knowledge, on the other hand, can more easily be 
carried on via long distances (David and Foray, 1995).  
The dichotomy between tacit and codified knowledge has often been used indirectly in the 
literature to study the role of geographic proximity in collaborations. However, this approach 
has been criticized as difficult to measure. In particular, the implicitness of knowledge is 
conceptually vague (Cowan, David and Foray, 2000). Numerous scholars, therefore, have 
presented a number of alternatives. For example, Asheim and Coenen (2005) and Asheim and 
Gertler (2009) classify knowledge into three categories: analytical, synthetic and symbolic. The 
first mainly refers to the scientific knowledge employed to understand and explain empirical 
phenomena. Synthetic knowledge is defined as know-how and is more tacit and problem-
driven. Symbolic knowledge is related to cultural meaning such as texts, films, and fashion 
designs. Although this classification has been used recently in a few studies (Mattes, 2012; 
Davids and Frenken, 2017), it does not describe different types of knowledge relevant to R&D. 
In this context, Broström (2010) suggests an alternative classification of knowledge, dividing 
the R&D process into three phases: learning and impulses (benefits for the first phase of the 
R&D cycle), short-term projects (benefits for the last phase of the R&D cycle) and long-term 
projects. Although this classification is focused on R&D, it does not directly consider the nature 
of knowledge. Furthermore, Broström (2010) adopts the perspective of the user, rather than the 
knowledge producer, the firm.  
In studies that acknowledge the diversity of knowledge in the R&D departments of MNCs, in 
particular for the science-based sector, it has been observed that certain R&D activities are 
highly tacit while others are more codified. This distinction has been used to characterize basic 
versus applied science knowledge, which is the most common way to classify scientific 
knowledge and R&D activities (Stokes, 1997). Basic science knowledge is the understanding 
of a scientific phenomenon based on experience accumulated by individuals (Lim, 2004). More 
precisely, the Organization for Economic Cooperation and Development defines it as ‘an 
experimental or theoretical work undertaken primarily to acquire new knowledge of the 
underlying foundation of phenomena and observable fact (OECD, 2011). Basic science 
knowledge is relatively tacit: it cannot be articulated verbally and is based on experience 
accumulated by individuals (Lim, 2004). It follows that basic science knowledge needs face-
to-face interaction and geographic proximity to be transferred. Applied science knowledge, on 
the other hand, seeks to produce knowledge for a specific end-use (NSF, 2006). It is more 
codified than basic science and can be more easily transmitted through written documents that 
allow it to travel long distances (Castellani and Zanfei, 2006). 
Next to the distinction between basic and applied science knowledge areas, this thesis argues 
that another way to distinguish between tacit and codified knowledge is by identifying areas 
that are core and areas that are exploratory to the firms. Companies generally have a few core 
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knowledge areas in which they have a high level of internal R&D knowledge they can exploit. 
In contrast, firms also have a number of knowledge areas, called exploration knowledge areas, 
where the level of internal R&D knowledge is lower than in core areas and they aim to develop 
new knowledge. This distinction is related to the internal knowledge of the firm and in 
particular to the choice of the firm to access new knowledge outside its core areas and leverage 
existing internal knowledge with external knowledge (Koza and Lewin, 1998; Rothaermel, 
2001; Beckman, Haunschild and Phillips, 2004). 
In literature, the dichotomy between core and explorative knowledge areas can be linked to the 
concepts of exploitation and exploration of knowledge in processes of organizational learning 
and technological innovation which was first introduced by March (1991). Exploitative as ‘the 
use and development of things already know’ and exploration is defined as ‘a pursuit of new 
knowledge’ (March, 1991; Levinthal and March, 1993). Looking at the role of geographic 
proximity, the exploration of knowledge, linked to the exploration knowledge areas in firms, 
is considered more codified and easy to transfer across long distances compared to the 
exploitation of knowledge (Miller, Zhao and Calantone, 2006). However, the exploitation of 
knowledge, defined as the core knowledge areas in firms, is the main source of innovation in 
firms and its knowledge transfer is closely controlled. Thus, these core knowledge areas 
consequently benefit from short distances to be transferred (Kale, Singh and Perlmutter, 2000; 
Cantwell and Mudambi, 2011). Explorative knowledge requires flexibility to assimilate 
knowledge from a diversity of skills and continuous scanning for new technological 
opportunities globally dispersed (Hansen, Nohria and Tierney, 1999).  
Thus, the use of the dichotomies basic versus applied science knowledge, and core vs 
explorative knowledge to describe the knowledge created in R&D collaborations gives 
possibilities to look at the difference in the nature of knowledge in research-based sectors. 
2.3.2 Collaborators at the organizational level 
R&D collaborations in MNCs can involve a diversity of external organizations such as 
universities, research institutes and companies. Each of these collaborative actors is 
characterized by a particular type of knowledge that MNCs entering into R&D collaborations 
aim to access. 
The geography literature has mostly focused on university-industry collaborations. Academia 
is the most important external organization that collaborates with science-based MNCs. 
Universities are considered the ‘holy grail’ of basic scientific knowledge and the base of 
breakthrough innovations. The knowledge embedded in universities is mostly tacit in nature 
and transferred verbally by individual researchers (Arora and Gambardella, 1990; Owen-Smith 
and Powell, 2004). Anselin, Varga and Acs, (2000) find that universities increase the 
innovation output of firms within a distance of about 50–75 miles. Tijssen (2009) observes that 
firms tend to collaborate locally with universities to gain access to research infrastructure and 
recruit highly skilled academics. Though most of the geography literature is limited to 
university-industry collaboration, academia is only one of the actors involved in R&D 
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collaborations with MNCs. The literature suggests that the diversity of external organizations 
contributes to a company’s innovative performance (Duysters and Lokshin, 2011; De Leeuw, 
Lokshin and Duysters, 2014). Thus, it is important to look at the knowledge that MNCs access 
from hospitals, research institutes and companies. For example, in the case of the 
pharmaceutical sector, hospitals are the primary source of applied knowledge (Cockburn and 
Henderson, 1996, 2001). MNCs collaborate with hospitals at long distances to access this type 
of knowledge (Glickman et al., 2009; Hoekman et al., 2012). 
Additionally, the difference between external organizations is often linked to the concept of 
institutional proximity. Institutional proximity is defined by Boschma (2005) as the distance 
between two organizations in terms of norms and values. For example, universities are 
primarily focused in the creation of new knowledge and education. Private companies are 
driven by commercialization,  focusing on knowledge that can be used for competitive 
advantage and profit (Dasgupta and David, 1994). Thus, collaborations between companies 
and universities cannot be considered institutionally proximate. Focusing on the geographic 
dimension of collaboration, Boschma (2005) and the related literature argue that institutional 
proximity compensates for the lack of geographic proximity and vice-versa (Boschma, 2005; 
Ponds, van Oort and Frenken, 2007; D’Amore et al., 2013). R&D collaborations between 
organizations that lack institutional proximity are more likely over short distances. This lack is 
compensated by the creation of mutual trust through face-to-face and informal interactions 
(Ponds, van Oort and Frenken, 2007; Balland, Boschma and Frenken, 2015). 
In sum, most scholars have assessed the role of geographic proximity in R&D collaboration 
between firms and external organizations using the concept of institutional proximity. It is 
important when studying geographic proximity to consider the type of knowledge that a MNC 
aims to access through the collaboration with that external organization.  
2.3.3 Collaborators at the individual level, star scientists 
Finally, another way to describe the different types of knowledge in R&D collaborations is to 
study the heterogeneity of the knowledge embedded in individuals.  
During R&D collaborations, knowledge is created through the interactions of individuals. 
Individuals are the locus of knowledge (Powell, 1998) and knowledge is created by them and 
through their interactions, not by the organization itself (Nonaka, 1991). Company employees 
and their embedded knowledge are critical ingredients to gain a competitive advantage for an 
organization. Firms create value through the selection, development and use of human capital 
(Grant, 1996a). The distribution of knowledge is heterogeneous and extremely skewed in 
organizations. Only a small group of individuals contributes to the production of knowledge in 
an organization (Lotka, 1926; Price, 1963). More specifically, these highly skilled individuals 
are commonly referred to as ‘star scientists’ (a term coined by Zucker and Darby, 1996). Star 
scientists play a primary role in the scientific knowledge creation of a firm and thus are a unique 
source of innovative competence (Henderson and Cockburn, 1994). Furukawa and Goto (2006) 
find that stars in science were responsible for a disproportionally large number of publications 
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in scientific journals and were thus engaging in the creation of new knowledge. In particular, 
they embed tacit knowledge and combine it with the genius and vision in the most promising 
areas of research. Beyond their knowledge, they also provide access to large networks that have 
extraordinary value for access to external knowledge (Henderson and Cockburn, 1994; Zucker 
and Darby, 1996; Lacetera, Cockburn and Henderson, 2004; Azoulay, Graff Zivin and Wang, 
2010). Star scientists act as boundary spanners, bridging organizational and environmental 
boundaries (Hess and Rothaermel, 2011).  
In the context of R&D collaborations, most of the literature has focused on the role of academic 
star scientists. Authors have shown that university star scientists involved in R&D 
collaborations with firms influence positively the number and average quality of firm 
innovations (Zucker and Darby, 1996, 2001; Baba, Shichijo and Sedita, 2009). Furthermore, 
Azoulay, Zivin and Sampat (2011) discuss the labour mobility of elite academic life scientists. 
They suggest that the interactions between academic scientists and industry professionals may 
require more face-to-face meetings than those involving only academics. As mentioned before, 
star scientists hold tacit knowledge and thus their collaborations require geographic proximity 
between the organizations involved (Audretsch and Feldman, 1996; Paci and Usai, 2000). 
In sum, the literature acknowledges the role of geographic proximity in collaborations 
involving star scientists. However, very few authors study the role of firms and star scientists 
in collaborations (for exception Hess and Rothaermel, 2011). 
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3 RESEARCH SETTING: MULTINATIONAL 
PHARMACEUTICAL COMPANIES  
The research setting for my thesis focuses on pharmaceutical MNCs for both personal and 
scientific reasons. Prior to starting my Ph.D. research, I worked as a lean manufacturing 
engineer for a multinational medical technology company. Over this experience, the lean 
manufacturing methodology taught me how to uncover what adds value to a project by 
reducing everything else by a better understanding of the innovation behind the R&D process 
of the industry. In particular, I had the possibility to look closely at how R&D is conducted 
inside a firm and became interested in how knowledge production is dependent on external 
organizations from different sectors. After that, I wanted to investigate more deeply the concept 
of innovation systems and I started working as a research assistant at the Karolinska Institutet. 
During this project, I researched the university innovation system and conducted several 
interviews with university professors. I noted how their experiences and importance of R&D 
collaborations with the industry, and in particular with pharmaceutical companies, have 
changed in the last 20 years. From these two different personal experiences, I developed the 
idea behind my Ph.D. project. My experience inside the life sciences sector has inspired me to 
look at R&D collaborations from a firm perspective. 
From a scientific perspective, the pharmaceutical sector is a suitable arena in which to study 
R&D collaboration because in no other industry are science, research and development so 
crucial for the innovation process (Munos, 2009; Kessel, 2011). Furthermore, R&D mainly 
relies on complex and basic science knowledge, the sources of expertise are widely dispersed 
and development requires coordination between different actors (Calero, Van Leeuwen and 
Tijssen, 2007; Plotnikova and Rake, 2014). 
Thus, the research setting of this thesis is the pharmaceutical industry. In particular, Paper I is 
focused on pharmaceutical innovation, looking at new molecular entities (NMEs) approved by 
the regulatory authority of the United States (US), the Food and Drug Administration (FDA). 
Papers II and III are centred around six pharmaceutical MNCs (Pfizer, AstraZeneca, Eli Lilly, 
GlaxoSmithKline, Novartis and Takeda) which belong to the top-20 largest companies 
according to revenue and R&D expenditures in 2012 (they were still part of this list in 2019). 
These MNCs have adopted different innovation and collaboration strategies, represent different 
cultures and are geographically distributed.  
In the next sections, I explain the knowledge and collaboration dynamics in the pharmaceutical 
industry.  
3.1 KNOWLEDGE IN THE DRUG DISCOVERY AND DEVELOPMENT 
PROCESS 
The innovation process of pharmaceutical companies is commonly called the ‘drug discovery 
and development process’ and can be divided into two main phases: discovery and 
development (Figure 1). The distinction between the discovery and development stages reflects 
the different knowledge characteristics, professional training and expertise required in the 
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process. The discovery stage establishes the theoretical base of the new drug. In the clinical 
development stages, all the results from basic science, preclinical pharmacology and safety are 
applied to see whether the scientific theory can be used into a valuable new drug for patients. 
Drug discovery is characterized by basic science knowledge, an invariability exploration of the 
unknown, and the resulted drug may end up with compounds quite different from the expected 
results. The development stage, in contrast, needs to follow the guidelines from the regulator 
using standard experimental protocols. It is characterized by applied science knowledge that in 
this case is called clinical science knowledge (Cockburn and Henderson, 1996, 2001; 
Cockburn, Henderson and Stern, 1999; Moodysson, Coenen and Asheim, 2008). 
In particular, the discovery stage aims to understand the mechanism and the process of the 
disease. First, the disease area is chosen and the therapeutic need to be addressed is delineated. 
Next, the biochemical, cellular or pathological mechanism that will be targeted are identified, 
and if it results in positive outcomes, a molecular drug target is identified. Then, the lead 
structure is established, followed by design, testing and the optimization of a small number of 
drug candidates judged suitable for the development process. After the identification of drug 
candidates, the preclinical test starts, where the mechanism of absorption, distribution, 
metabolism, excretion, and toxicology of the drug candidates are studied and tested on animals. 
At the end of the preclinical stage, the first approval is required by the authorities to start human 
clinical trials. In the case of the US, considered the leading drug-discovering country in the 
world, the first approval required by the FDA to start human clinical trials is called the 
Investigational New Drug application. In this first approval step, the results from the preclinical 
testing are checked by the authorities. They analyse the side effects and other safety features of 
a drug candidate, the drugs’ chemical structure. In addition, the manufacturing process of the 
drug is considered (Hill, Rang and Vallance, 2012).  
If the drug candidate receives approval for human clinical trials, the development stage starts, 
which is focused on proving the effectiveness and safety of the drug for humans. It includes all 
the steps from a drug candidate to the approval of the drug for marketing by the appropriate 
regulatory authorities, for example, the FDA in US. Clinical development involves four phases. 
Phase I examines the clinical pharmacology, involving a relatively small group of healthy 
people, to study how the body takes in and discards the drug. Then it looks at the side effects 
and the outcomes of the drug. Phase II focuses on exploration, proof of concept, confirmatory 
efficacy and dose range finding. This phase is mostly concentrated on the safety of the drug, 
looking both at the short-term side effects and the efficacy of the drug against a specific 
condition. Phase III concentrates on confirmatory, large-scale efficacy and safety. It involves 
more than a few hundred patients and is the most expensive and time-consuming phase of the 
drug development process. An NME that successfully passes through all these stages finally 
enters the approval stage when an application is filed by the drug sponsor to obtain sales and 
marketing approval from the regulatory authority. In the US, the application is called a New 
Drug Application (NDA) and is submitted to the FDA (Hill, Rang and Vallance, 2012). 
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Figure 1| Drug discovery and development process in the US. NME is a New Molecular 
Entities and NDA is a New Drug Application. 
3.2 TRENDS IN THE PHARMACEUTICAL INDUSTRY  
In recent decades, the pharmaceutical sector has faced a productivity crisis (Pammolli, 
Magazzini and Riccaboni, 2011). The number of NMEs approved has decreased and the cost 
of bringing a drug to the market has grown constantly. The cost to put a drug on the market 
was more than $2 billion and the failure rate approximates 95% in 2013 (DiMasi, Grabowski 
and Hansen, 2016). Furthermore, the long time to market is due to the complexity of clinical 
studies and a relatively stringent regulatory environment (Munos, 2009). Secondly, the patents 
behind several blockbuster drugs have expired, triggering competition in the generics market. 
In particular, between 2009–2013, of the top 20 best-selling drugs in the world, 18 went off 
patent (Munos, 2009; Kessel, 2011). 
Looking at the six pharmaceutical MNCs selected for this thesis, Figure 2 shows that R&D 
expenditures between 2000 and 2010 increased, while revenues started to decrease around 
2010. Novartis, for example, in the period 2003–2010, increased its research and development 
investment by 171%, thus becoming the biggest R&D spender in the entire pharmaceutical 
industry. However, between 2010 and 2011, the revenues decreased in all six MNCs. These 
trends can be associated with the productivity crisis in the pharmaceutical industry. 
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Figure 2| R&D investment between 2000 and 2012; B. Revenues between 2000 and 2012 of 
six pharmaceutical MNCs. Source: Company Annual Reports.  
In this challenging and dynamic environment, the drug discovery and development process is 
more distributed and pharmaceutical MNCs are heavily engaged in R&D collaborations. Rafols 
et al. (2014) explore the R&D of the major European and US pharmaceutical firms by 
examining their publication activities during the period 1995–2009. They observe a relative 
increase in the publications of these firms with external organizations, suggesting a tendency 
to outsource. Furthermore, different external organizations are involved depending on the 
phase of the drug discovery process. Figure 3 depicts the involvement of external organizations 
in various phases of the R&D process. The discovery stage involves mostly collaborations with 
academia, research institutes and biotech companies, for example. These organizations are 
crucial to the generation of basic science knowledge in firms (Arora and Gambardella, 1990; 
Owen-Smith and Powell, 2004). Hospitals and contract research organizations collaborate 
more frequently with pharmaceutical companies in the development stage. Clinical trials are 
conducted in hospitals and frequently managed by contract research organizations. Thus, 
through these collaborations, MNCs have access to clinical science knowledge.  
 
Figure 3| Drug discovery and development process in pharma and critical partners. NME: 
New Molecular Entities; NDA: New Drug Applications (in the US).  
In addition, globalization has facilitated collaborations across long distances and MNCs are 
using a combination of local and long-range collaborations. For example, in the development 
phase, pharmaceutical MNCs have started to offshore clinical trials to non-traditional clinical 
research countries far from their R&D sites or coordinated from distant R&D sites (Glickman 
et al., 2009). Furthermore, the globalization trend has increased competition as firms compete 
on a global scale and focus more on core knowledge areas where they have a stronger 
knowledge base to compete and create a more flexible structure for the exploration knowledge 
areas.  
As a consequence of this trend, a change in the structure of pharmaceutical MNCs can be 
observed. Traditionally pharmaceutical MNCs were organized with one or more large central 
R&D laboratories, but in the last ten years, they have shifted to decentralized R&D structures, 
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with several R&D locations around the world to access local knowledge. A new trend is 
emerging that expresses the view that ‘smaller is better’, with the creation of small and 
autonomous discovery entrepreneurial units active in the interaction with external partners 
(Douglas et al., 2010). To this end, pharmaceutical companies have adopted different solutions. 
For example, they create small R&D hubs inside a university to work side by side with 
academic researchers or organizations that are more science-driven and less bureaucratic, close 
to the entrepreneurial model of the biotechnology industries. Another example is the small units 
tasked with identifying and developing external drug discovery opportunities with shared costs, 
risks and rewards (Gassmann and Von Zedtwitz, 2003; Munos, 2009; Kessel, 2011).  
The rising interest in external collaboration and the globalization trend of MNCs is illustrated 
in the positive growth of the number of publications of the six selected pharmaceutical MNCs 
between 2000 and 2012 (Figure 4). The overall number of publications increased as well as 
publications with external organizations, while the number of internal written publications 
remained constant (Figure 4a). Further, looking at the geographic location of the organizations 
involved in the publications (Figure 4b), the number of countries involved has increased in the 
time period studied. This rise is also generated by the change of the structure of MNCs as they 
have increased the number of their R&D locations spread around the world to access local 
specialized knowledge. 
 
 
Figure 4| A. Number of MNCs publications, B. Number of countries involved in the 
publications of the six MNCs selected between 2000 and 2012. The line related to external 
organizations shows the number of countries related to the external organizations that 
collaborate with the MNCs selected. The line related to MNC internal sites depicts the number 
of countries of the R&D sites of the MNCs. Source: publications from the Scopus database. 
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4 AIM AND CONTRIBUTION OF THE THESIS 
The aim of this thesis is to investigate the role of geographic proximity in R&D collaborations 
of MNCs when creating, accessing and embedding different types of knowledge. The research 
setting is the pharmaceutical industry.  
My starting point is that the role of geographic proximity may vary according to the nature of 
knowledge and the type of actors who are involved in the R&D collaboration. I examine these 
aspects by: 
1. Differentiating between the nature of knowledge (basic vs. clinical science 
knowledge, and core vs explorative knowledge). 
2. Differentiating between actors 
a. on the organizational level (external organizations such as a university, 
hospital, research institute or company). 
b. on the individual level (star scientists vs other individuals). 
As to the nature of knowledge, I refer to the knowledge that is created within the collaboration. 
For actors on the organization level, I refer to the knowledge that is accessed from external 
organizations. Concerning actors on the individual level, I refer to the knowledge that is 
embedded within individuals in the firm that form the loci of collaborations. These three levels 
address the role of geographic proximity in R&D collaborations in more depth.  
The main contribution of this thesis to the existing literature on geographic proximity and R&D 
collaborations is to show that the role of geographic proximity in collaborations needs to be 
assessed in relation to the type of knowledge involved. To my knowledge, this is one of the 
first studies that goes beyond the firm-level and takes as the unit of analysis an R&D 
collaboration of a firm based upon knowledge type.  
The thesis consists of three papers. Their aims and contributions are explained in detail in the 
next sections and an overview is presented in Table 1. 
4.1 AIM AND CONTRIBUTION OF THREE PAPERS 
In my first paper entitled “Potential effects of increased openness in pharma: The original 
knowledge behind new drugs“, I seek to provide a general descriptive analysis of how the 
degree of openness and the importance of geographic proximity in R&D collaborations are 
changing the drug discovery and development process. This paper contributes to the overall 
aim of the thesis, by looking at the changing role of geographic proximity in terms of the 
location of the organizations behind new drugs. Furthermore, I look at the different types of 
actors - on the organizational level – that are involved in the creation of new drugs. Previous 
studies have analysed the organizations in the drug discovery and development process 
(Kneller, 2010; Stevens et al., 2011). These studies have only focused on the organizations that 
are granted new drugs and have studied the patents behind the new drugs to identify these 
organizations. However, the development of drugs is the result of a wide range of organizations 
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involved beyond the direct production of patents. To have a better overview of the 
organizations involved, this article used the prior art references in the patents behind new drugs 
to identify the organizations that contribute to the knowledge underpinning new drugs. In 
addition, this article looks at the type of organizations that contribute to the development of 
new drugs change over time. 
The second paper of my thesis, entitled ‘The importance of geographical distance to different 
types of R&D collaboration in the pharmaceutical industry’, deals with the role of geographic 
proximity in R&D collaborations of MNCs based upon types of knowledge. This paper 
contributes to the overall aim of this thesis by studying the nature of knowledge and the actors 
involved at the organization level. As mentioned earlier, the geography literature to date has 
considered knowledge to be a homogenous phenomenon, without looking into differences in 
the access and creation of knowledge and their geographic logic (Mattes, 2012). This paper 
fills this gap by providing a better understanding of the factors that influence the role of 
geographic proximity in collaboration based upon types of knowledge. The collaborations are 
divided by the nature of knowledge into basic science vs applied science, and core vs 
exploration knowledge. Furthermore, this paper also studies the role of geographic proximity 
in collaboration distinguishing between different actors such as universities, hospitals, and 
companies.  
Finally, Paper III, entitled ‘Should they stay or should they go? How the closure of MNC R&D 
sites affects regional collaboration’, focuses on the effect that the closure of MNCs R&D sites 
has on access to local knowledge. Collaborations with actors are affected differently depending 
on the type of organizations involved. Further, the involvement of certain individuals such as 
star scientists is also shown to influence how well MNC can continue to collaborate with local 
actors. The existing literature on closures and their regional consequences is limited, and most 
of the studies have focused on the consequences of closures for employees (Boschma, 2005; 
Holm and Østergaard, 2015). However, this paper provides a better understanding of how the 
role of geographic proximity in collaborations is affected by the closure of R&D sites 
depending upon the type of knowledge involved. To my awareness, this study is one of the first 
empirical attempts to quantitatively identify the impact a closure may have on local R&D 
collaborations and thereby access to knowledge. The study provides a more nuanced 
understanding of the importance of geographic proximity for local collaborations. Second, it 
gives insights on how to minimize the negative loss of knowledge due to closure for companies 
and regions. 
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Paper Title Objective Paper- Methodology 
Paper 1-  
Potential effects of increased openness in pharma: 
The original knowledge behind new drugs. 
Determine the change in the degree of openness and the 
importance of geographic proximity in terms of 
location of the organizations behind new drugs in 
pharmaceutical R&D. 
Method: Bibliometrics and Patentometrics 
Sample: NMEs approved by FDA between 2000 and 2015 
Data analysis: Descriptive statistics and social network 
analysis. 
Paper 2-  
The importance of geographical distance to different 
types of R&D collaboration in the pharmaceutical 
industry.  
 
Investigate the factors that influence the role of 
geographic proximity in collaborations, looking at the 
nature of knowledge (basic science, clinical science, 
core knowledge and exploration knowledge) and the 
types of actors at the organizational level (university, 
hospital and company) involved. 
Method: Bibliometrics  
Sample: Publications of six pharmaceutical MNCs between 
2000 and 2012. 
Data analysis: Regression analysis using gravity models. 
Paper 3-  
Should they stay or should they go?  
How the closure of MNC R&D sites affects regional 
collaboration. 
Investigate the effect of the closure of MNC R&D sites 
on local external collaborations, distinguishing between 
types of actors at the organizational (university, hospital 
and company) and individual level (star scientists). 
Method: Bibliometrics 
Sample: Publications of five pharmaceutical MNCs between 
2000 and 2014. 
Data analysis: Regression analysis using difference-in-
difference models. 
Table 1| Details of the three papers.
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5 METHODOLOGY 
5.1 RESEARCH PROCESS 
The research process of the thesis is illustrated in Figure 5. I first conducted exploratory 
interviews with high-level managers at the MNCs to examine the role of geographic proximity 
in R&D collaborations in MNCs. These interviews served to identify how companies are 
working with R&D collaborations and provided a basic understanding of MNCs collaboration 
strategies. 
 
 
Figure 5| Research process 
The interviews triggered me to quantify the changing role of openness and geographic 
proximity in the drug discovery and development process. To do that, I decided to use an 
explorative approach. Specifically, geographic proximity is analysed with attention to 
globalization and the increased collaborations between countries. The results of this first 
explorative phase in the research process are found in Paper I. 
Further into the research process and based on the results of the Paper I, I employed a deductive 
approach to test the existing theory of the importance of geographic proximity in R&D 
collaborations. A deductive approach focuses on ‘developing a hypothesis (or hypotheses) 
based on existing theory and then designing a research strategy to test the hypothesis’ (Wilson, 
2014). I began with the theory on the importance of geographic proximity in R&D 
collaborations. Then new hypotheses were formulated to test this theory and I considered how 
the role of geographic proximity may differ depending on the knowledge involved in 
collaborations. In particular, I distinguished between the nature of the knowledge and the types 
of actors involved in collaborations. Thus, the hypotheses were based on the relationship 
between geographic distances, nature of the knowledge and type of actors involved in R&D 
collaborations. They were then tested using multiple regression analysis. The results of this 
deductive approach are found in Paper II.  
Based on the initial interviews, it emerged that MNCs are characterized by continuous changes 
in their R&D structure. These changes may include the opening, closure, and relocation of 
R&D sites due to for example mergers and acquisitions, access to market and local 
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competences, political pressure, access to the specific target population and governmental 
incentives. The closures of R&D sites by MNCs are not unusual. Furthermore, the interviewers 
underline that when a MNC decides to close an R&D site, this may have implications for local 
collaborations and star scientists. Based on this information, I decided to test the role of 
geographic proximity on R&D collaborations when a local R&D site is closing using a 
deductive approach similar to Paper II. Looking at the knowledge type involved in R&D 
collaborations, I distinguished according to the actors at organizational as well as individual 
level. The results of this study are found in Paper III. 
I use a quantitative approach in all papers. Quantitative methods are used to test the theoretical 
hypotheses and measure the relationship between variables to explain a phenomenon (Denzin 
and Lincoln, 1998). One reason for using quantitative methods in this thesis is that this 
approach provides me with the opportunity to obtain an overview of each collaboration of a 
MNC and to compare this across MNCs. In addition, the choice to use quantitative methods is 
related to the research setting of this thesis: MNCs. MNCs are large companies that collaborate 
intensively. Thus, quantitative methods can provide broad and general conclusions of the use 
of R&D collaborations in MNCs. The quantitative methods used in this thesis are bibliometric 
and patentometric methods. In the next section, the reasons for this choice are explained. 
5.2 BIBLIOMETRIC AND PATENTOMETRIC AS METHODS 
Different methods have been used in the literature to analyse R&D collaborations and 
knowledge exchange. The most common methods to measure the outcome of collaborations in 
science, and in particular R&D collaborations, are bibliometric and patentometric methods.  
The bibliometric method applies to scientific publications. It is based on the concept that the 
core of scientific research is the production of ‘knowledge’ and scientific literature is the 
constituent presentation of that knowledge creation process, the output of R&D activity. 
Publications are one way for researchers to make new knowledge available to the scientific 
community and to claim it as intellectual property. Price (1963), in his seminal work ‘Little 
Science-Big Science’, underlines that ‘a scholarly publication is not a piece of information but 
an expression of the state of a scholar or a group of scholars at a particular time’. Furthermore, 
according to Cockburn and Henderson (Cockburn and Henderson, 1996) co-authorship of 
papers is evidence of a significant, sustained and productive interaction between researchers in 
different organizations. In particular, publications involving multiple organizations serve as a 
proxy for collaborations between individuals and organizations. In this case, the article includes 
more than one author and location, suggesting that the authors come from different 
organizations.  
Similar to publications, the patentometric method identifies patents taken by multiple 
organizations as a proxy for collaborations. Patents have been the most frequently used 
indicator of knowledge transfer and technological change (Narin and Noma, 1987; Agrawal 
and Henderson, 2002). Patents have been used to evaluate the innovation performance of 
organizations and individual researcher. Furthermore, patent analysis has become an important 
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tool to explore technological collaboration and measure the output of the innovation system 
(McAleer and Slottje, 2005; Gao, Guan and Rousseau, 2011). Since patent data is publicly 
available and regularly updated, it provides a specific and detailed indicator for analysing how 
public research is developed by industries (Cohen, Nelson and Walsh, 2002).  
A number of authors have identified reasons to support publications or patents as 
representations of a robust method to measure R&D collaborations. First, publications and 
patents are public information, accessible to everyone, and the results of their analyses can be 
reproduced using the same method. Second, they are scalable. Analyses can be performed at 
individual, organizational, national or international levels (Katz and Hicks, 1997). Third, 
among other indicators used to map collaborations, analyses of publications or patents are 
methods that can be uniformly applied to all organizations. They are also commonly used in 
science-based sectors such as the pharmaceutical industry (Tijssen, 2009, 2012). 
However, there are several significant limitations in using patents and publications as a proxy 
for collaborations. First, not all the collaborations between organizations result in a patent or a 
co-publication. In the context of this thesis, the complexity of the knowledge generation 
process in the pharmaceutical industry requires the involvement of many different actors across 
sectors and disciplines that might not publish or patent. Therefore, those involved, for example, 
in technology development and clinical trials are overlooked using the above methods. Second, 
collaboration is the result of individual interactions and therefore equates to a fuzzy 
phenomenon, about which publications or patents only reveal aspects of the actual 
collaboration. Furthermore, collaborations can take place in various forms and for a number of 
reasons, for example giving general advice, providing materials, sharing ideas and data, and 
the production of a patent or publication. A bibliometric or patentometric study is not able to 
reveal these characteristics. Patents and publications may also overemphasize the contribution 
of certain actors. Not all the names on a publication are responsible for the work. Indeed, some 
publications list authors for purely social reasons. This is the case of academia in publications 
or industry in patents. On the contrary, university researchers might, for example, publish 
results of joint efforts without listing in the publication the involvement of industry 
organizations. Thus, these collaborations cannot be identified using a bibliometric method. 
Finally, the date when a paper or patent is published does not reflect the time when the research 
activities were performed. Further, citations both in patents and publications may be added 
because of strategic reasons even when they do not reflect actual knowledge sources (Katz and 
Martin, 1997; Moed, Glänzel and Schmoch, 2004). 
The difference between publications and patents as a proxy of collaborations is the difference 
between science and technology. Patents are related to a technical invention and publication to 
science. Furthermore, universities are focused on publishing and they want to publish their 
results quickly to increase their (citation) impact. However, the industry is oriented to 
commercialize knowledge. Firms seek to keep their knowledge internally, rather than to 
publish in scientific papers (Dasgupta and David, 1994). As a result, they may want to limit the 
disclosure of funding until they apply for a patent. However, with the increasing importance of 
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R&D collaborations, industries are increasingly publishing in particular in science-based 
industries like the pharmaceutical sector (Rafols et al., 2014). Furthermore, comparing 
publications and patents, the knowledge in R&D collaborations is covered more widely by 
scientific publications than patents because knowledge must be novel to qualify for a patent. 
In sum, publications and patents do not capture all the collaborations and their aspects. 
However, I assumed that significant R&D collaborations lead to these outputs in most cases in 
the pharmaceutical MNCs.  
5.3 SAMPLE  
The research setting of this thesis is the pharmaceutical sector. I have selected two different 
samples in order to first exploratively investigate the openness of pharmaceutical industry and 
then to focus on the role of the geographic proximity in R&D collaborations. First, I have 
selected 102 NMEs between 2000 and 2015, focusing on four time periods (2000, 2005, 2011 
and 2015). Second, I chose six pharmaceutical MNCs (Pfizer, AstraZeneca, Eli Lilly, 
GlaxoSmithKline, Novartis and Takeda) that belong to the top-20 largest companies according 
to revenue and R&D expenditure in 2012. They continue to top the list for 2019. These 
companies have been selected because they have adopted strategic, cultural and geographic 
differences. Based on interviews with R&D managers of these MNCs, I also checked that these 
firms adopted different collaboration strategies. Selecting companies with non-identical 
collaboration strategies, cultures and geographic distribution allow me to generalize my results.  
This thesis uses publications and patents in both samples as the main proxy of R&D 
collaborations. There are several databases that index scientific publications, such as for 
example, Scopus, Web of Science and Google Scholar. The dataset for this project has been 
built on publications extracted from Scopus, a database of scientific documents edited by 
Elsevier and launched in 2004. Scopus contains 33 million records of which 16 million include 
references going back to 1996; 17 million pre-1996 records go back as far as 1841. Scopus lists 
scientific articles from a wide collection of publishers and includes information such as 
authors´ name, title, publication date, abstract, etc. I chose Scopus rather than Web of Science 
as it links author names with their affiliations in the period analysed in this thesis (this was 
introduced by Web of Science around 2008–2009). This is important in the disambiguation of 
individuals across the publications and, for this thesis, in the study of the actors at the individual 
level. Moreover, Scopus includes broader and robust information than Google Scholar (Yang 
and Meho, 2006). For these reasons, I selected Scopus as the publication database of choice in 
this thesis. 
For the patent, this thesis used United States Patent and Trademark Office (USPTO) data 
because the US market is the leading market for pharmaceutical drugs and Paper I is focused 
on NMEs granted by Food and Drug Administration (FDA) that is the agency that approved 
new drugs in the United States. 
In particular, Paper I analyses the main patents of the 102 NMEs approved in 2000, 2005, 2011 
and 2015 by the FDA. The patents behind these drugs were extracted from the New Drug 
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Application (NDA) documents and Orange books of the Food and Drug Administration (FDA). 
The NDA is the application by the drug sponsor to formally propose the approval of a new 
drug by the FDA in the US and it is collected by the same agency in the public database 
DRUG@FDA. The drug sponsor applying to the NDA must include all active patents covering 
the NMEs in the NDA document to ensure that no other company holds the rights to that drug. 
However, some of the online NDA documents in the DRUG@FDA did not include patent 
information. In these cases, the Orange book hard copy version was used to search for patents. 
Orange Book is the common name of the yearly publication called “Approved Drug Products 
with Therapeutic Equivalence Evaluations”. From the 102 NMES, 322 patents were identified. 
From these patents we collected the citations as publications and patents. The total sample 
consists of 322 main patents and 3,607 citations (publications and patents).  
Paper II uses publications between 2000 and 2012 derived from the selected six pharmaceutical 
MNCs in collaboration with at least one external organization. The database includes 24,561 
publications and 17,631 external organizations.  
Finally, Paper III reviews the publications of the selected pharmaceutical MNCs and identifies 
605 local external organizations affected by the closure of five R&D sites and 860 local external 
organizations of five control sites between 2000 and 2014. 
5.4 DATA COLLECTIONS 
I built up a database including both the patents and publications.  
Publications and patents contain information describing many characteristics of collaborations. 
In particular, a bibliometric record includes author names and affiliation(s) (including 
institution, country and city), year of publication, citations and keywords. The inclusion of 
author addresses enables the identification of interactions both inside (different R&D locations 
and departments) and outside of a company. Similar to a publication, a patent document 
includes a variety of information, such as the name of the inventor(s), address(es) and the name 
of the organization receiving the patent. In addition, citations are included in the patents.  
In order to investigate the change of openness in R&D collaborations, the main patents behind 
new drugs were analysed looking at the name of the organizations receiving the patent. 
However, these organizations might be present mainly for marketing reasons, having little to 
do with the actual scientific knowledge contribution. Thus, the citations in the main patents 
were also analysed to have a better understanding of the knowledge behind new drugs. A 
citation can be a patent or a publication.  
In order to analyse the geographic proximity between MNC and collaborators, the address of 
the authors and inventors of all publications and patents of the MNCs were cleaned. Next, the 
cities of the collaborating organizations and MNC R&D sites were used to determine the 
geographical coordinates (longitude, latitude) of each location using Google Maps. In addition, 
looking at the effect on collaborations after the closure of an R&D site, I defined local 
collaboration as a collaboration between MNCs and external local organizations within 100 
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km from a closed or control R&D site. I identified those local collaborations with the 
publications of MNCs that were co-published with a local organization. 
The information contained in the publications and patents also allowed for them to be 
differentiated by the nature of knowledge and the type of actors involved in R&D collaboration.  
5.4.1 Categorization of the nature of knowledge  
To categorize the publications according to the nature of knowledge (basic science vs clinical 
science knowledge; core vs exploration knowledge), the keywords of the publication were 
identified. Keywords identify the major themes of a publication and typically consist of 
Medical Subject Heading (MeSH) terms, a comprehensive controlled vocabulary that is used 
by the National Library of Medicines to classify publications and books on life sciences and 
medicine. In other words, they are labels assigned to each article in Medline in order to describe 
what the article is about. The use of MeSH terms captures the heterogeneity among papers 
within a journal; it is a more specific approach compared to the traditional CHI index, based 
on the classification of the journal in which an article is published (Hamilton, 2003). Keywords 
are used in this thesis to classify the publications into basic vs clinical science knowledge and 
core vs exploration knowledge. 
In addition, it is important to underline that citations from the main patents can be considered 
basic science knowledge because the organizations filed the patents for the new drugs when 
the drug is at the discovery phase 
5.4.2 Categorization of the types of actors at the organizational level 
Based on the address(es) of authors and inventors, an actor was classified according to type at 
the organizational level, i.e. university, hospital, research institute, company and other 
(governmental agency, foundations, etc.).  
5.4.3 Categorization of the types of actors at the individual level 
Finally, to categorize the publications on the individual level, I have adopted the definition of 
star scientists by Rothaermel and Hess (2007). A star scientist is defined as a MNC researcher 
who publishes at a rate of three standard deviations above the average MNC scientists over the 
previous ten years. Star scientists were identified in the database of the total publications for 
each MNC looking at the names of authors in the publications. In this way, a list of star 
scientists was created and matched with the names of authors of the local publications. 
5.5 ANALYSIS 
For the analysis, I used descriptive statistics, social network analysis (SNA) and multiple 
regression models.  
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5.5.1 Social network analysis 
In Paper I, I used social network analysis (SNA) to quantify the changing role of openness and 
geographic proximity in the drug discovery and development process. Many scholars use SNA 
to map and measure the relationships and flows between people, groups and organizations. In 
Paper I, SNA is applied to investigate and visualize the connection between the actors involved 
in patents and publications. The descriptive statistics were also used in Paper II and III for the 
base of the regression models.  
5.5.2 Econometric approach 
In Papers II and III, I used multiple regression models to test the importance of geographic 
proximity in R&D collaborations for different types of knowledge. Multiple regression models 
allow for the prediction of the number of collaborations between two organizations based on 
the geographic distances between collaborators and the type of knowledge involved.  
In particular, in Paper II, I used the gravity model as a multiple regression model. In the 
geography literature, the gravity model has been used to approximate spatial interactions 
between locations (Ponds, van Oort and Frenken, 2007; Hoekman, Frenken and van Oort, 
2009). This has enabled me to control for other determinants – types of knowledge – that affect 
MNC collaborations in addition to geographic distance. The model is based on the ‘gravity 
equation’, an analogy to the Newtonian theory of gravity. In Paper II, the gravity model has 
been used to estimate the effect of geographical distance on the number of collaborations of a 
MNC. Generally, a gravity model assumes that the number of R&D collaborations between a 
MNC R&D site and an external organization will be directly proportional to the product of 
their economic mass (measured by the number of total publications of the MNC R&D site and 
the external organization) and inversely proportional to the distance between them. Thus, the 
dependent variable of the gravity model is the number of publications as a proxy of R&D 
collaborations of the MNCs. The geographic distance and the nature of the knowledge of each 
publication are the independent variables. The types of actors at the organizational level were 
included as control variables. 
In Paper III, I tested hypotheses regarding the effects of closures of MNC R&D sites on the 
number of local collaborations and the involvement of star scientists. Building a regression 
using a difference-in-difference model (DID), I estimated the difference in the number of 
collaborations between a MNC and a local organization affected by the closure, assessed 
against a control group. Following the work of Ashenfelter and Card (1985), the DID model 
has become a popular tool to estimate the effect of a policy change or treatment in the medical 
field (Meyer, 1995; Heckman, Lalonde and Smith, 1999; Blundell and Costa Dias, 2009; 
Lechner, 2010). This model is used to estimate outcomes before and after the policy or 
treatment intervention. In Paper III, the treatment intervention is the closure of the R&D site. 
The dependent variable is the number of collaborations. The types of actors at the 
organizational and individual levels are analysed using two independent variables. 
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6 RESULTS 
In the next section, I first present the explorative results on the changing role of openness in 
the drug discovery and development process (section 6.1). Then, the results on the changing 
role of geographic proximity in relation to the types of knowledge in R&D collaborations are 
outlined (section 6.2).  
6.1 INCREASING OPENNESS OF PHARMACEUTICAL MNCS 
In accordance with earlier studies, I observe that the number of organizations involved in the 
main patents of newly approved drugs increased between 2000 and 2015. However, this 
increased number is more pronounced for organizations that are involved in the citations of the 
main patents. The main patents of newly approved drugs are still granted to few organizations. 
Instead, the citations in the main patents involved an increasing number of organizations 
between 2000 and 2015 that indirectly contributed to drug discovery (Table 2). In addition, the 
organizations involved in the citations are more external organizations than the companies 
granted new drugs.  
Using SNA, I have analysed the degree of interconnectedness of the organizations involved in 
cited patents to determine the extent to which those granted new drugs share the same or new 
organizations in the citations. Figure 6 illustrates the networks of the organizations involved in 
the citations in 2000, 2005, 2011, 2015. Each red node represents the NMEs and the black 
nodes represent the organizations involved in the citations. The edges illustrate the knowledge 
contribution from the organization in the citations to NMEs. It can be observed that the 2000 
network has fewer organizations (black nodes) shared between NMEs than in 2015. Thus, 
organizations applying for drugs are increasingly relying on knowledge from the same 
organizations. This is, for example, the case of California University, which contributed to 16 
new drugs in 2015.  
 
2000 2005 2011 2015 
NMEs that includes at least one main patent 22 16 20 32 
Main Patents 62 48 50 162 
Organizations in the main patents 28 17 29 49 
Organizations in the citations  322 535 1088 1087 
Internal 10 17 19 23 
External 312 518 1069 1064 
Table 2| Number of the organizations behind the new drug approved.  
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Figure 6| External organization networks over the sample years: (A) 2000, (B) 2005, (C) 2011 and (D) 2015. Each black node identifies an external 
organization; red nodes signify NMEs. The labels of the red nodes are the organizations granted new drugs. Each line represents an external organization 
contributing to a new drug.  
A B 
C D 
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6.2 GLOBALIZATION AND THE DIVERSE GEOGRAPHIC DISTANCES IN 
COLLABORATIONS  
The effect of globalization can be observed with the increased number of countries in the 
organizations behind a new drug, in particular the external organizations included in citations. 
The number of countries of the organizations involved in the citations in 2015 is almost three 
times the number in 2000 (Table 3).  
Considering that globalization and informational communication technologies have facilitated 
collaborations at long distances, I first tested with gravity and DID models whether geographic 
proximity still matters in collaborations. The results show that geographic distances negatively 
affect R&D collaborations. This is also the case for local collaborations affected by the closure 
of an R&D site.  
Next, to further investigate the role of geographic proximity in R&D collaboration in MNCs, I 
analysed the relationship between geographic distance and the types of knowledge (nature of 
the knowledge, type of actors at the organizational and individual level) in collaborations. 
 
2000 2005 2011 2015 
NMEs 7 6 5 6 
Organizations in the main patents 8 6 7 12 
Organizations in the citations  17 32 36 45 
External Organizations in the citations     
Universities 13 26 32 38 
Hospitals 9 15 16 28 
Research Institutes 10 19 21 27 
Companies 10 13 18 18 
Table 3| Number of unique countries of organizations involved in the main patents and in 
their citations (Paper I). 
6.2.1 Geographic proximity matters for collaboration in basic science and 
core knowledge  
The nature of the knowledge involved in the R&D collaborations is investigated to distinguish 
between basic science, clinical science, core and exploration knowledge areas. The results 
show that clinical science and core knowledge collaborations are the highest in number 
between the R&D collaborations of the selected MNCs (Table 4). 
The relationship between the mean number of collaborations and the geographical distance 
between MNC R&D sites and external organizations looking at the nature of the knowledge 
(basic science, clinical science, core and explorative) is presented in Figure 7. The geographical 
distances of R&D collaborations involving a MNC range from 0 km to almost 20,000 km. The 
distribution of the distance is twisted as 25% of collaborations take place within 400 km. In 
particular, Figure 7(a) shows that the mean number of collaborations in the range of 100 km is 
higher for basic science knowledge areas than for clinical science knowledge areas. Beyond 
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100 km, the mean number of collaborations in clinical science knowledge area is always higher 
than that of basic science areas. Furthermore, Figure 7(b), adding the distinction core and 
exploration to the basic and clinical science knowledge areas, shows that the mean number of 
R&D collaborations is higher in clinical science-core knowledge than in clinical science-
exploration knowledge at all geographic distances. However, the opposite result is observed 
for the R&D collaborations that create basic science knowledge.  
I subsequently tested the effect of the relationships between geographic distances and the nature 
of knowledge on the number of R&D collaborations with gravity models. Geographic 
proximity displayed greater importance for R&D collaborations in basic science compared to 
clinical science knowledge areas. Finally, in both basic science and clinical science knowledge 
areas, geographical distance affected more negatively the number of collaborations in core 
knowledge areas than in exploration knowledge areas.  
 
 N Mean SD Min Max 
Total number of collaborations 41 650 2.311 4.391 1 274 
Basic science 5 721 1.864 2.411 1 72 
Clinical science  37 759 2.273 3.945 1 202 
Basic science-core  3 415 1.545 1.667 1 40 
Basic science-exploration  3 497 1.571 1.711 1 40 
Clinical science-core 26 155 1.943 3.101 1 162 
Clinical science-exploration  21 280 1.667 2.157 1 106 
Table 4| Descriptive statistics of the nature of knowledge in R&D collaborations of the six 
selected MNCs (Paper II). 
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(a) 
  
(b) 
 
 
 
 
 
 
 
 
 
Fig. 7| Mean number of collaborations for geographical distance intervals between MNC 
R&D sites and external organizations with confidence intervals according to the nature of the 
knowledge (Paper II). 
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6.2.2 Geographic proximity matters for collaborations with universities 
Next, the type of actors at the organization level involved in the R&D collaborations are 
studied, separating the external organization into universities, hospitals, research institutes and 
companies. Universities are the most important external organizations involved indirectly in 
the discovery and development of a new drug and their importance increased between 2000 
and 2015 (Table 5). The results in Table 5 show that the role of universities increases by a 
factor of four, while hospitals and companies grow by a factor of three between 2000 and 2015. 
It is important to underline that the citations from the main patents can be considered basic 
science knowledge because the organizations filed the patents for the new drugs when the drug 
is at the discovery phase.  
Furthermore, looking at the increased number of countries in organizations indirectly involved 
in the creation of new drugs, this increase is less pronounced for companies compared to other 
types of actors, such as universities, hospitals and research institutes (Table 3). One explanation 
could be that companies behind new drugs are still based in the leading countries of the 
pharmaceutical industry such as the US, UK, Switzerland, Japan and Germany. In contrast, 
universities, hospitals and research institutes are instead increasingly spread around the globe, 
in line with the globalization trend.  
In the R&D collaborations, we can observe that hospitals are the most important collaborator 
in terms of the number of collaborations with MNCs and in particular in clinical science 
knowledge areas. Instead, universities- MNC collaborations are the most frequently in basic 
science knowledge. 
Based on these results, I tested the relation between the types of actors at the organization level 
and the geographic distances in collaborations with the gravity models. I found that the role of 
geographic proximity differs between collaborations that involve universities, hospitals and 
companies. More specifically, if an R&D collaborator is a university, the role of geographic 
proximity is more important compared to other types of organizations. In contrast, R&D 
collaborations that involve hospitals are positively affected by geographic distances. This 
means that MNCs and hospital can successfully collaborate at long distances.  
Further, similar results were shown by the DID models looking at the type of actors when R&D 
collaborations are affected by the closure of a local MNC R&D site. Local R&D collaborations 
when an R&D site closes are more important if the collaboration involves a university 
compared to a hospital or a company.  
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 2000 2005 2011 2015 
Universities 
(median number of external organizations per NME) 
123 
(3) 
244 
(7) 
472 
(7.5) 
490 
(11.5) 
Hospitals 
(median number of external organizations per NME) 
44 
(0) 
72 
(1.5) 
134 
(1.5) 
152 
(1) 
Research Institutes 
(median number of external organizations per NME) 
57 
(0) 
80 
(1) 
177 
(2.5) 
151 
(3) 
Companies 
(median number of external organizations per NME) 
88 
(2.5) 
122 
(2.5) 
286 
(10) 
271 
(7.5) 
Table 5| Number of actors at the organizational level in the citations of the main patents 
behind new drugs (Paper I). 
6.2.3 Importance of star scientists in the retention of local collaborations 
Finally, the relationships between geographic distances and types of actors at the individual 
level were studied with DID models, focusing on the R&D collaborations involving star 
scientists.  
In accordance with earlier studies, the involvement of star scientists with MNCs positively 
affects the number of collaborations. Furthermore, local R&D collaborations are less 
negatively affected by the closure of R&D sites if they are linked to star scientists of MNCs 
before the closure compared to if star scientist were not involved. Finally, I compared the effect 
of the location of star scientists distinguishing between local (located at the R&D site) versus 
non-local (located elsewhere in the company). The local R&D collaborations involving a 
MNCs star scientist are less affected by the closure if the star scientist was not located in that 
R&D site that is closing. These results suggest that star scientists are important for MNC to 
retain R&D collaborations and to continue to be able to have access to local knowledge after 
the closure of an R&D site. 
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7 DISCUSSION 
The aim of this thesis was to investigate the role of geographic proximity in R&D 
collaborations of pharmaceutical MNCs when creating, accessing and embedding different 
types of knowledge. I find that the role of geographic proximity is dependent on the nature of 
the knowledge and type of actors that are involved in the collaboration.  
In the next section, I discuss the changing role of openness in the drug discovery and 
development process and in R&D collaborations. Then, the role of geographic proximity in 
R&D collaborations is discussed. 
7.1 INCREASING OPENNESS OF PHARMACEUTICAL MNCS 
In accordance with earlier studies (Chesbrough, 2003; Tijssen, 2009; Simpson and Reichman, 
2013; Rafols et al., 2014; Crescenzi, Nathan and Rodríguez-Pose, 2016), the results of my 
thesis point to an increasing openness of the pharmaceutical industry with a high number of 
R&D collaborations and different organizations involved in the drug development process. 
Pharmaceutical innovation is no longer a stand-alone activity conducted by a few big 
pharmaceutical companies in isolation.  
The openness of the pharmaceutical industry was investigated looking at how the knowledge 
behind new drugs has changed over time. Pharmaceutical MNCs are increasingly relying on 
external organizations to create new drugs. However, this increased openness was found to be 
mostly indirect. This means that the patents and the ownership of the NMEs are still internal to 
the MNCs; external organizations are used only indirectly to access new knowledge. Thus, 
although the pharmaceutical industry is using more external organizations, I still observed a 
traditional division of the drug discovery and development process. The private sector is mainly 
responsible to test new drug compounds in the clinical phase, and they still own the main 
patents behind new drugs. The public sector is the main driver of basic research to clarify the 
underlying mechanisms and pathways of disease and detect promising drug compounds. Thus, 
despite the increasing involvement of universities, companies sponsoring drug development 
still own the main patents behind them. 
Collaborators are increasingly shared between MNCs developing drugs. Thus the same 
external organizations contribute indirectly to the creation of several NMEs. These are mainly 
‘elite institutions’ and MNCs collaborate with them regularly to access new knowledge from 
the best clinical researchers and scientists. Firms arrange funding, human resources, 
infrastructure, compound libraries and technologies, whereas academic and clinical partners 
supply in new ideas for the drug targets.  
Looking deeper into how MNCs use external collaborations, this thesis shows that MNCs use 
R&D collaborations to create, access and embed different types of knowledge that contribute 
to an internal heterogeneous knowledge pool. For example, R&D collaborations of MNCs are 
more common in the clinical science and core knowledge areas compared to basic science and 
exploration types of knowledge. Looking at the type of actors at the organizational level, I 
 39 
found that universities are the most important knowledge contributor to get access to basic 
science in collaborations for MNCs. This is in line with earlier literature. For example, Cohen, 
Nelson and Walsh (2002) conclude that a third of industrial R&D projects relied on research 
carried out in academia. Additionally, the results show that universities are also crucial actors 
in the drug discovery and development process and their relative importance has increased 
between 2000 and 2015. This can be explained by Bayh-Dole Act (Mowery and Sampat, 2005), 
the growing number ‘translational research’ activities by goverments (Zerhouni, 2005), and 
public-private research partnerships (Stiglitz and Wallsten, 1999) that have promoted the 
growing number of interactions between universities and companies in the last 40 years. On 
the other side, MNCs collaborate with universities to share costs and access the knowledge of 
highly skilled academic researchers (Rothaermel and Hess, 2007). 
Finally, looking at the type of actors at the individual level, this thesis shows that the knowledge 
embedded in star scientists internal to the MNCs influences positively the number of 
collaborations. To this point, prior literature has suggested that collaborations with top 
researchers have a positive effect on the innovative performance of firms (Baba, Shichijo and 
Sedita, 2009). In fact, star scientists are considered an important source of knowledge for a 
company not only through their own research but also by being part of a large scientific network 
(Lacetera, Cockburn and Henderson, 2004; Rothaermel and Hess, 2007).  
7.2 DIFFERENT TYPES OF KNOWLEDGE DETERMINE THE ROLE OF 
GEOGRAPHIC PROXIMITY 
In combination with the increased openness, globalization has facilitated collaborations at long 
geographic distances and pharmaceutical MNCs have adopted a combination of local and 
distant collaborations. This trend is observed in the study of the organizations that contributed 
to new drugs. The results show that the number of involved organizations from different 
countries has increased. But also that MNCs choose to open R&D locations throughout the 
world to harness locally external capabilities and to exploit local knowledge (Gassmann and 
Reepmeyer, 2005; Rusu, Kuokkanen and Heier, 2011).  
Due to an increasing number of global collaborations, considerable attention has been paid in 
the literature to the (changing) role of geographic proximity. In accordance with earlier studies, 
this thesis shows that – despite the globalization trend and the development of information 
communication technologies – geographic proximity still matters in R&D collaborations 
(Ponds, van Oort and Frenken, 2007; Douglas et al., 2010; Abramovsky and Simpson, 2011; 
Plotnikova and Rake, 2014). In particular, geographic proximity positively affects the number 
of collaborations of MNCs. Being located at short distance facilities the number of 
collaboration between an MNC and an external organization. By studying the effect of closures 
of R&D sites, I find that MNCs partly loose access to local knowledge. Thus, local R&D sites 
act as temporary co-location spaces for collaborations between MNCs and local organizations.  
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This thesis also shows that the role of geographic proximity in R&D collaborations is complex 
and, that the nature of knowledge created and the types of actors involved in the collaborations 
have to be taken into account.  
7.2.1 Basic science and core knowledge collaborations are more sensitive 
to geographic proximity 
Considering the nature of knowledge, collaborations are less affected by geographic distance 
in clinical science than in basic science knowledge areas. Basic science knowledge is highly 
tacit and characterized by its serendipitous nature. This can be explained by looking at the 
different platforms adopted by the major pharmaceutical MNCs under the umbrella of ‘open 
innovation’ to facilitate R&D collaborations. For example, Pfizer established the Center for 
Therapeutic Innovation, a network for academic collaborators. It aims to bridge the gap 
between early scientific discoveries and translation into new drugs, building flexible and small 
Pfizer locations inside major universities in the US. Another example is the open innovation 
initiative by GlaxoSmithKline called Open lab at 3 Cantos, a research centre concentrating on 
diseases common in developing countries such as malaria and tuberculosis. The centre supports 
visiting researchers from universities to carry out research there. In 2002, Novartis launched its 
Institute for BioMedical Research in Cambridge (Massachusetts) to gain access to local 
universities and research hubs.  
In contrast, clinical science knowledge can be considered more codified knowledge and thus 
can more easily be transferred through collaborations at geographic distances. The number of 
clinical trials carried out in so-called emerging regions, especially in Eastern European, Latin 
American and Asian countries, increased in the last 20 years. Thiers, Sinskey, and Berndt 
(2008) showed that between 2002 and 2006, the number of biopharmaceutical clinical trial sites 
in the emerging regions grow with 21.3%. The reasons behind this shift include lower costs, 
faster patient recruitment, establishment of contract research organizations focused on global 
clinical trials, and access to new markets (Drain et al., 2018). Additionally, Haeussler and Rake 
(2017) have shown that the knowledge base of emerging regions plays an important role in the 
location decision for clinical trials by pharmaceutical companies. Emerging countries see the 
opportunities to enhance their national innovative capacity with the active participation of 
domestic scientists in clinical research projects together with scientists for developed countries.  
Finally, in both basic and clinical science, R&D collaborations in core knowledge areas need 
closer geographic proximity than in exploration knowledge areas. Companies are exploring 
potential new areas to invest in and using distant collaborations to learn about market trends 
and the newest technologies (Bathelt, Malmberg and Maskell, 2004). Instead, collaborations in 
core areas rely on long-term relationships and trust. These knowledge areas are the main 
income sources for organizations and require close proximity (Kessel, 2011). 
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7.2.2 Universities are more sensitive collaborators concerning geographic 
proximity  
Looking at the actors at the organizations level, this thesis shows that R&D collaborations are 
more negatively influenced by distance if the interaction involves a university compared to a 
hospital. A similar result is found in my analysis of the effect of the closure of R&D sites on 
local collaborations. The presence of a local MNC R&D site is more important when it comes 
to setting up and maintaining collaborations with universities or research institutes compared 
to other types of organizations. These results are in line with those of the previous section about 
the nature of the knowledge. In fact, academia embeds mostly basic science knowledge that 
due to its tacit nature depends on short distances and face-to-face interactions to be transferred 
(Arora and Gambardella, 1990; Owen-Smith and Powell, 2004). When MNCs access 
knowledge from hospitals, it is mainly with the aim to access clinical science knowledge which 
is more accessible over distance. 
These results are also in line with the role of institutional proximity introduced by Boschma 
(2005). He argued that geographic proximity is neither a prerequisite nor sufficient for 
successful collaboration and it can compensate for the lack of institutional proximity (when 
actors are far apart in norms, practices and/or incentives) in collaborations. Hence, MNC-
university collaborations require geographic proximity for their lack of institutional proximity.  
7.2.3 Star scientists compensate for the lack of geographic proximity 
Finally, this thesis looked at the role of geographic proximity when the collaborations involve 
particular individuals, such as star scientists. The results suggest that star scientists of MNCs 
play a positive role in the retention of local R&D collaborations after the closure of an R&D 
site. When an R&D site is closing, the risk that the MNC may lose out on local knowledge is 
mitigated by the presence of star scientists in the collaborations. The results show that even 
though the star scientists are located elsewhere within the MNC they have a positive effect on 
local collaborations.  
Thus, geographic proximity in R&D collaboration is less important when it involves a star 
scientist. This result highlights the boundary-spanning roles of star scientists and their 
importance for collaborations at geographic distances. Star scientists often have a large network 
and can serve as a channel for the firm to reach the scientific community (Arora and 
Gambardella, 1990). These individuals act as a bridge between organizations (Lacetera, 
Cockburn and Henderson, 2004) and “creators of knowledge road” between different units and 
geographic areas (Maier, Kurka and Trippl, 2007). 
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8 CONCLUSIONS 
Increased openness in the innovation process of pharmaceutical MNCs has been presented as 
a solution to the productivity crisis faced by these companies. Pharmaceutical MNCs are 
increasingly collaborating with a variety of organizations, individuals and expanding into 
different knowledge areas. Considering this increased openness, a key strategic question for 
MNCs is how to create, assimilate and embed knowledge effectively in R&D collaborations. 
This thesis highlights the role of geographic proximity in R&D collaborations and how it is 
dependent on the knowledge types involved. MNCs are characterized by high internal diversity 
and the collaborations of a MNC differ depending on the stages of the innovation process and 
research and therapeutic areas involved. Thus, companies need to develop different strategies 
for collaborations depending on the type of knowledge involved. The importance of knowledge 
types in R&D collaboration supports the view that an organization or individual knowledge 
base involved determines the success of R&D collaborations. This suggests that MNCs need 
to attract and involve the right organizations and individuals in their collaborations.  
Nevertheless, my analysis shows that there is room for universities to play a more active role 
in the drug innovation process given their unique knowledge base. It is therefore important to 
continue to promote ‘translational research’ and public-private partnerships not only to increase 
collaborations but also to encourage a more active role for academia and organizations from 
other sectors in the creation of innovation. Furthermore, the analysis of the role of geographic 
proximity and star scientists when an R&D site of MNCs is closing highlights the crucial role 
of star scientists for successful external collaborations of MNCs. Star scientists are important 
for MNCs not only because of their expertise and knowledge base but also because of their 
ability to span collaborations over longer distances and compensate for the absence of local 
R&D sites and mitigate the negative effect of the closure of a MNC R&D site.  
Finally, the link between knowledge type and geography emphasizes the importance of 
considering geography in R&D management. Managers, when they need to close or open a 
MNC R&D site, must consider that the importance of geographic proximity and face-to-face 
interactions depends on the nature of the knowledge created and accessed in that specific 
location. Thus, the knowledge type of the MNC’s R&D site can be considered a location driver 
as well as a strategic characteristic to consider when a MNC decides to close or open a R&D 
site. From a policy standpoint, these arguments are important to keep in mind when local actors 
are trying to attract foreign MNCs and when facilitating and supporting the development of 
collaboration. 
8.1 FUTURE WORKS 
This thesis has mainly contributed to increasing our understanding of the role of geographic 
proximity in MNCs R&D collaborations. However, R&D collaboration is only one of the 
mechanisms of the so-called open innovation strategy of a firm. Companies vary considerably 
in their modes and strategies regarding how to access external knowledge. These different 
modes, take many forms, such as joint-equity, ventures, recruitment and acquisitions (Powell, 
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Koput and Smith-Doerr, 1996). The strategy towards external knowledge can affect why some 
organizations gain more from external interactions than others (Dahlander and Gann, 2010). 
Thus, it could be interesting to compare the role of R&D collaborations and the importance of 
geographic proximity therein with other modes and strategies used by MNCs to access external 
knowledge. 
Another interesting area for future research could be an in-depth investigation into knowledge 
creation, looking specifically at each R&D collaboration of an MNC. This can provide insights 
for firms on how to engage in successful collaborations. For example, the in-depth study might 
look at how the knowledge being created in the R&D collaborations involving hospitals differs 
from those with universities.  
Furthermore, the role of individuals, and in particular star scientists, in collaborations and teams 
have received a lot of attention recently in the literature (for example Bennett and Gadlin, 2012; 
Bozeman and Boardman, 2014). However, a key question remains: What is the role of 
individuals in R&D collaboration? Additionally, are they increasingly becoming network 
orchestrators? 
Finally, the main focus of this thesis is on geographic proximity. Institutional proximity has 
been considered only marginally in relation to geographic proximity. However, proximity is a 
multi-dimensional concept that includes geographic, institutional, organizational, social and 
cognitive proximity. To be able to further understand R&D collaborations, other dimensions 
of proximity need to be considered. Thus, it could be interesting to investigate how the different 
proximity dimensions vary depending on the type of knowledge involved in R&D 
collaborations. For example, I would expect that cognitive proximity is more important for 
collaborations in basic science knowledge due to its tacit nature compared to clinical science 
knowledge. In fact, if the cognitive distance is too large, the actors involved will not understand 
each other and will not be able to interpret and assimilate knowledge; this is particularly 
difficult for tacit knowledge (Nooteboom, 1992). In addition, several authors have shown that 
the dimensions of proximity may be complementary to each other or they may also act as 
substitutes (Boschma, 2005; D’Amore et al., 2013; Davids and Frenken, 2017). A future 
research question might ask how does complementarity vary according to different dimensions 
of proximity and knowledge? 
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